The Pricing of Breakthrough Drugs: Theory and Policy Implications
Author
Abstract
Suggested Citation
DOI: 10.1371/journal.pone.0113894
Download full text from publisher
References listed on IDEAS
- Levy, Moshe & Nir, Adi Rizansky, 2012. "The utility of health and wealth," Journal of Health Economics, Elsevier, vol. 31(2), pages 379-392.
- Amy Finkelstein & Erzo F. P. Luttmer & Matthew J. Notowidigdo, 2013.
"What Good Is Wealth Without Health? The Effect Of Health On The Marginal Utility Of Consumption,"
Journal of the European Economic Association, European Economic Association, vol. 11, pages 221-258, January.
- Finkelstein, Amy & Luttmer, Erzo F. P. & Notowidigdo, Matthew J., 2008. "What Good Is Wealth without Health? The Effect of Health on the Marginal Utility of Consumption," Working Paper Series rwp08-036, Harvard University, John F. Kennedy School of Government.
- Amy Finkelstein & Erzo F.P. Luttmer & Matthew J. Notowidigdo, 2008. "What Good Is Wealth Without Health? The Effect of Health on the Marginal Utility of Consumption," NBER Working Papers 14089, National Bureau of Economic Research, Inc.
- Viscusi, W Kip & Evans, William N, 1990. "Utility Functions That Depend on Health Status: Estimates and Economic Implications," American Economic Review, American Economic Association, vol. 80(3), pages 353-374, June.
- Z. John Lu & William S. Comanor, 1998. "Strategic Pricing Of New Pharmaceuticals," The Review of Economics and Statistics, MIT Press, vol. 80(1), pages 108-118, February.
- F. Clementi & M. Gallegati, 2005.
"Pareto's Law of Income Distribution: Evidence for Germany, the United Kingdom, and the United States,"
Papers
physics/0504217, arXiv.org, revised Mar 2006.
- Fabio Clementi & Mauro Gallegati, 2005. "Pareto's Law of Income Distribution: Evidence for Grermany, the United Kingdom, and the United States," Microeconomics 0505006, University Library of Munich, Germany.
- Nirei, Makoto & 楡井, 誠, 2009. "Pareto Distributions in Economic Growth Models," IIR Working Paper 09-05, Institute of Innovation Research, Hitotsubashi University.
- William S. Comanor & Stuart O. Schweitzer, 2007. "Determinants of drug prices and expenditures," Managerial and Decision Economics, John Wiley & Sons, Ltd., vol. 28(4-5), pages 357-370.
- Patricia M. Danzon & Mark V. Pauly, 2002. "Health Insurance and the Growth in Pharmaceutical Expenditures," Journal of Law and Economics, University of Chicago Press, vol. 45(S2), pages 587-613.
- Sloan, Frank A. & Kip Viscusi, W. & Chesson, Harrell W. & Conover, Christopher J. & Whetten-Goldstein, Kathryn, 1998. "Alternative approaches to valuing intangible health losses: the evidence for multiple sclerosis1," Journal of Health Economics, Elsevier, vol. 17(4), pages 475-497, August.
- Joseph Persky, 1992. "Retrospectives: Pareto's Law," Journal of Economic Perspectives, American Economic Association, vol. 6(2), pages 181-192, Spring.
- Reekie, W Duncan, 1978. "Price and Quality Competition in the United States Drug Industry," Journal of Industrial Economics, Wiley Blackwell, vol. 26(3), pages 223-237, March.
- DiMasi, Joseph A. & Hansen, Ronald W. & Grabowski, Henry G., 2003. "The price of innovation: new estimates of drug development costs," Journal of Health Economics, Elsevier, vol. 22(2), pages 151-185, March.
Citations
Citations are extracted by the CitEc Project, subscribe to its RSS feed for this item.
Cited by:
- Hanna, E. & Toumi, M. & Dussart, C. & Borissov, B. & Dabbous, O. & Badora, K. & Auquier, P., 2018. "Funding breakthrough therapies: A systematic review and recommendation," Health Policy, Elsevier, vol. 122(3), pages 217-229.
Most related items
These are the items that most often cite the same works as this one and are cited by the same works as this one.- Moshe Levy & Adi Rizansky, 2014. "Market failure in the pharmaceutical industry and how it can be overcome: the CureShare mechanism," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 15(2), pages 143-156, March.
- Arthur E. Attema & Marieke Krol & Job Exel & Werner B. F. Brouwer, 2018. "New findings from the time trade-off for income approach to elicit willingness to pay for a quality adjusted life year," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 19(2), pages 277-291, March.
- Dorte Gyrd‐Hansen, 2017. "A Stated Preference Approach to Assess whether Health Status Impacts on Marginal Utility of Consumption," Health Economics, John Wiley & Sons, Ltd., vol. 26(10), pages 1224-1233, October.
- Kools, Lieke & Knoef, Marike, 2019. "Health and consumption preferences; estimating the health state dependence of utility using equivalence scales," European Economic Review, Elsevier, vol. 113(C), pages 46-62.
- W. Kip Viscusi, 2019. "Utility functions for mild and severe health risks," Journal of Risk and Uncertainty, Springer, vol. 58(2), pages 143-166, June.
- Padmaja Ayyagari & Daifeng He, 2017. "The Role of Medical Expenditure Risk in Portfolio Allocation Decisions," Health Economics, John Wiley & Sons, Ltd., vol. 26(11), pages 1447-1458, November.
- Hammitt, James K., 2022. "Prevention, Treatment, and Palliative Care: The Relative Value of Health Improvements under Alternative Evaluation Frameworks," TSE Working Papers 22-1339, Toulouse School of Economics (TSE).
- James K. Hammitt, 2022. "Prevention, treatment, and palliative care: The relative value of health improvements under alternative evaluation frameworks," Post-Print hal-03965174, HAL.
- Richard Peter, 2021. "A fresh look at primary prevention for health risks," Health Economics, John Wiley & Sons, Ltd., vol. 30(5), pages 1247-1254, May.
- Patricia M. Danzon & Eric L. Keuffel, 2014. "Regulation of the Pharmaceutical-Biotechnology Industry," NBER Chapters, in: Economic Regulation and Its Reform: What Have We Learned?, pages 407-484, National Bureau of Economic Research, Inc.
- Herrera-Araujo, Daniel & Rochaix, Lise, 2020.
"Does the Value per Statistical Life vary with age or baseline health? Evidence from a compensating wage study in France,"
Journal of Environmental Economics and Management, Elsevier, vol. 103(C).
- Daniel Herrera Araujo & Lise Rochaix, 2020. "Does the Value per Statistical Life vary with age or baseline health? Evidence from a compensating wage study in France," Post-Print hal-03353422, HAL.
- Daniel Herrera Araujo & Lise Rochaix, 2020. "Does the Value per Statistical Life vary with age or baseline health? Evidence from a compensating wage study in France," PSE-Ecole d'économie de Paris (Postprint) hal-03353422, HAL.
- Octave Jokung & Serge Macé, 2013. "Long-term health investment when people underestimate their adaptation to old age-related health problems," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 14(6), pages 1003-1013, December.
- Amy Finkelstein & Erzo F. P. Luttmer & Matthew J. Notowidigdo, 2009.
"Approaches to Estimating the Health State Dependence of the Utility Function,"
American Economic Review, American Economic Association, vol. 99(2), pages 116-121, May.
- Finkelstein, Amy N. & Luttmer, Erzo F. P. & Notowidigdo, Matthew J., 2009. "Approaches to Estimating the Health State Dependence of the Utility Function," Working Paper Series rwp09-002, Harvard University, John F. Kennedy School of Government.
- Finkelstein, Amy & Luttmer, Erzo F.P. & Notowidigdo, Matthew J., 2009. "Approaches to Estimating the Health State Dependence of the Utility Function," IZA Discussion Papers 3925, Institute of Labor Economics (IZA).
- Verniers, Isabel & Stremersch, Stefan & Croux, Christophe, 2011. "The global entry of new pharmaceuticals: A joint investigation of launch window and price," International Journal of Research in Marketing, Elsevier, vol. 28(4), pages 295-308.
- Herrera-Araujo, Daniel & Hammitt, James K. & Rheinberger, Christoph M., 2020. "Theoretical bounds on the value of improved health," Journal of Health Economics, Elsevier, vol. 72(C).
- Zheng, Jiakun, 2021. "Willingness to pay for reductions in health risks under anticipated regret," Journal of Health Economics, Elsevier, vol. 78(C).
- Xiaoyu Wang & Chunan Wang, 2020. "How Does Health Status Affect Marginal Utility of Consumption? Evidence from China," IJERPH, MDPI, vol. 17(7), pages 1-20, March.
- Rheinberger, Christoph M. & Herrera-Araujo, Daniel & Hammitt, James K., 2016.
"The value of disease prevention vs treatment,"
Journal of Health Economics, Elsevier, vol. 50(C), pages 247-255.
- Christoph M Rheinberger & Daniel Herrera-Araujo & James K. Hammitt, 2016. "The value of disease prevention vs treatment," Post-Print halshs-01626801, HAL.
- Christoph M Rheinberger & Daniel Herrera-Araujo & James K. Hammitt, 2016. "The value of disease prevention vs treatment," PSE-Ecole d'économie de Paris (Postprint) halshs-01626801, HAL.
- David Crainich, 2019.
"Effet des préférences individuelles sur la réussite à long terme des incitations financières à la réalisation d’objectifs de santé,"
Revue d'économie politique, Dalloz, vol. 129(4), pages 447-465.
- David Crainich, 2019. "Effet des préférences individuelles sur la réussite à long terme des incitations financières à la réalisation d’objectifs de santé," Post-Print hal-02108283, HAL.
- David Crainich & Louis Eeckhoudt & James Hammitt, 2015.
"The value of risk reduction: new tools for an old problem,"
Theory and Decision, Springer, vol. 79(3), pages 403-413, November.
- David Crainich & Louis Eeckhoudt & James K. Hammitt, 2013. "The Value of Risk Reduction: New Tools for an Old Problem," Working Papers 2013-ECO-13, IESEG School of Management.
- David Crainich & Louis R. Eeckhoudt & James K. Hammitt, 2014. "The value of risk reduction: new tools for an old problem," Post-Print hal-01533560, HAL.
Corrections
All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:plo:pone00:0113894. See general information about how to correct material in RePEc.
If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.
If CitEc recognized a bibliographic reference but did not link an item in RePEc to it, you can help with this form .
If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.
For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: plosone (email available below). General contact details of provider: https://journals.plos.org/plosone/ .
Please note that corrections may take a couple of weeks to filter through the various RePEc services.